Notably, despite this selectivity, PI4KB-Peptide-1 demonstrated superior antitumor efficacy compared to chloroquine, suggesting that preserving immune function and disrupting tumor metabolic remodeling are more critical for effectively treating RAS-mutant cancers than simply reducing nutrient scavenging. This evidence concerns the gene PI4KB and cancer.